Literature DB >> 9152974

Acute promyelocytic leukaemia in the all trans retinoic acid era.

T G DeLoughery1, S H Goodnight.   

Abstract

Bleeding diathesis is a common complication of acute promyelocyctic leukaemia (APL). Multiple haemostatic defects are found in most patients with APL, which often worsen following cytoreductive chemotherapy. Besides thrombocytopenia, most patients develop disseminated intravascular coagulation, systemic fibrinolysis or both. A major aim in treating haemostatic defects of APL is to prevent death or disability from bleeding until chemotherapy clears the malignant promyelocytes from the blood and bone marrow. The therapeutic options are discussed in this review and practical guidelines for treatment are outlined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9152974     DOI: 10.1007/bf02990936

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  100 in total

1.  "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity.

Authors:  H M Golomb; J D Rowley; J W Vardiman; J R Testa; A Butler
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

2.  Promyelocytic leukemia with multiorgan infarctions and large-vessel thrombosis.

Authors:  N Jetha
Journal:  Arch Pathol Lab Med       Date:  1981-12       Impact factor: 5.534

3.  Hemostatic and fibrinolytic parameters in patients with acute myeloid leukemia: activation of blood coagulation, fibrinolysis and unspecific proteolysis.

Authors:  W Speiser; I Pabinger-Fasching; P A Kyrle; S Kapiotis; A Kottas-Heldenberg; P Bettelheim; K Lechner
Journal:  Blut       Date:  1990-11

Review 4.  Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy.

Authors:  D I Feinstein
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage.

Authors:  S Hashimoto; T Koike; W Tatewaki; Y Seki; N Sato; T Azegami; N Tsukada; H Takahashi; H Kimura; M Ueno
Journal:  Leukemia       Date:  1994-07       Impact factor: 11.528

6.  Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia.

Authors:  F Rodeghiero; P M Mannucci; S Viganò; T Barbui; L Gugliotta; M Cortellaro; E Dini
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

7.  Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency.

Authors:  B S Schwartz; E C Williams; M G Conlan; D F Mosher
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

8.  Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.

Authors:  D Head; K J Kopecky; J Weick; J C Files; D Ryan; K Foucar; M Montiel; J Bickers; A Fishleder; M Miller
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

Review 9.  Acute promyelocytic leukemia.

Authors:  R P Warrell; H de Thé; Z Y Wang; L Degos
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245

10.  Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid.

Authors:  A B Federici; A Falanga; A Lattuada; N Di Rocco; T Barbui; P M Mannucci
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.